Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
LifeStance Health Group
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Digital Advancements And Telehealth Will Expand Mental Health Access
Key Takeaways AI-driven automation, differentiated clinician support, and telehealth expansion position the company for accelerated growth, improved margins, and outsized patient and clinician acquisition. Industry shifts toward value-based care and greater mental health coverage uniquely favor the company, enabling sustained top-line growth and superior long-term cash flow.
View narrative
US$10.00
FV
45.6% undervalued
intrinsic discount
15.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Ambarella
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Autonomous Vehicles And Edge AI Will Expand Secular Opportunities
Key Takeaways Expansion into edge AI and scalable infrastructure products could drive sustainable, above-expected growth in revenue, margins, and free cash flow across multiple high-value markets. Recurring software and services income, combined with a resilient supply chain and growing platform ecosystem, positions Ambarella for lasting market leadership in AI-powered solutions.
View narrative
US$95.00
FV
29.5% undervalued
intrinsic discount
17.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Peloton Interactive
AN
AnalystHighTarget
Consensus Narrative from 16 Analysts
Digital Health Expansion And Wearable Tech Will Transform Wellness Ecosystems
Key Takeaways Expansion into holistic wellness and AI-driven personalization positions Peloton for industry leadership, higher user retention, and increased subscriber value. Commercial segment growth, digital subscription focus, and strategic partnerships set the stage for substantial revenue diversification and structural margin expansion.
View narrative
US$16.64
FV
48.8% undervalued
intrinsic discount
2.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
PTC Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 16 Analysts
Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
Key Takeaways Accelerated adoption of key therapies, global expansion, and a robust rare disease portfolio position the company for sustained revenue and margin growth. Strategic partnerships, disciplined operations, and business development readiness enhance flexibility for value-creating deals and expanding innovative treatment pipelines.
View narrative
US$105.36
FV
53.7% undervalued
intrinsic discount
-8.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Verona Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Ohtuvayre Launch And EU Approval Will Unlock Future Markets
Key Takeaways Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential. Global regulatory advancements and strategic financing bolster potential for new revenue streams and acquisitions.
View narrative
US$106.22
FV
0.9% undervalued
intrinsic discount
83.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
3 days ago
author updated this narrative
Ultragenyx Pharmaceutical
AN
AnalystHighTarget
Consensus Narrative from 20 Analysts
Advanced Gene Therapies Will Drive Global Rare Disease Growth
Key Takeaways Rapid international expansion, innovative therapies, and strong patient outcomes position Ultragenyx for accelerated growth and greater market share than current expectations suggest. Scalable manufacturing, operational discipline, and advanced diagnostics are set to drive margin expansion and unlock a larger addressable market in rare diseases.
View narrative
US$128.00
FV
76.8% undervalued
intrinsic discount
46.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Sweetgreen
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Emerging Automation Will Drive Healthy, Sustainable Dining Trends
Key Takeaways Infinite Kitchens and new store formats are driving improved unit economics, operational consistency, and accelerating future margin and sales growth. Enhanced digital rewards and menu innovation are fueling rapid customer engagement, positioning Sweetgreen to capture greater market share amid rising demand for health-forward dining.
View narrative
US$21.00
FV
56.2% undervalued
intrinsic discount
19.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Exact Sciences
AN
AnalystConsensusTarget
Consensus Narrative from 23 Analysts
Humana, Centene And Medicare Coverage Will Increase Screening Access
Key Takeaways Broadening payer coverage and demographic trends toward an older population are positioning Exact Sciences for sustained and expanding revenue opportunities from core and new product offerings. Cost optimization initiatives, operational scale, and tech-driven efficiency improvements are enhancing profitability while product portfolio diversification increases market competitiveness and revenue streams.
View narrative
US$62.97
FV
27.6% undervalued
intrinsic discount
11.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
31
users have followed this narrative
3 days ago
author updated this narrative
Flutter Entertainment
AN
AnalystConsensusTarget
Consensus Narrative from 25 Analysts
Brazil And US Markets Will Unlock iGaming Opportunities
Key Takeaways Expansion in new markets, product innovation, and platform integration are expected to drive user engagement, market share, and sustained earnings growth. Structural cost efficiencies and deeper iGaming penetration should enhance margins, free cash flow, and shareholder returns over the long term.
View narrative
US$343.11
FV
14.5% undervalued
intrinsic discount
16.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies